FORM 9

NOTICE OF PROPOSED ISSUANCE OF LISTED SECURITIES (or securities convertible or exchangeable into listed securities 1)

| Please complete the following: | | | | |
|--|--|--|--|--|
| Name of Listed Issuer: Golden Leaf Holdings Ltd. (the "Issuer"). | | | | |
| Trading Symbol: <u>GLH</u> . | | | | |
| Date: <u>August 30, 2018</u> . | | | | |
| Is this an updating or amending Notice: □Yes X No | | | | |
| If yes provide date(s) of prior Notices: | | | | |
| Issued and Outstanding Securities of Issuer Prior to Issuance: 580,963,994 | | | | |
| Date of News Release Announcing Private Placement: <u>August 17, 2018; August 29, 2018</u> . | | | | |
| Closing Market Price on Day Preceding the Issuance of the News Release: <u>\$0.22;</u> | | | | |

1. Private Placement (if shares are being issued in connection with an acquisition (either as consideration or to raise funds for a cash acquisition), proceed to Part 2 of this form)

| Full Name & Residential Address of Placee | Number of Securities Purchased or to be Purchased | Purchase price per Security (CDN\$) | Conversion Price (if Applicable) | Prospectus Exemption | No. of Securities, directly or indirectly, Owned, Controlled or Directed | Payment Date(1) | Describe relations -hip to Issuer (2) |
|--|---|--|--|-------------------------|--|--------------------|--|
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

FORM 9 – NOTICE OF PROPOSED ISSUANCE OF LISTED SECURITIES

| (·) | details of expected payment date, conditions to release of funds etc. Indicate if the placement funds been placed in trust pending receipt of all necessary approvals. |
|-------|---|
| (2) | Indicate if Related Person. |
| | ssuance of non-convertible debt does not have to be reported unless it is a significant transaction as led in Policy 7, in which case it is to be reported on Form 10. |
| 1. | Total amount of funds to be raised: |
| 2. | Provide full details of the use of the proceeds. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material. |
| 3. | Provide particulars of any proceeds which are to be paid to Related Persons of the Issuer: |
| 4. | If securities are issued in forgiveness of indebtedness, provide details and attach the debt agreement(s) or other documentation evidencing the debt and the agreement to exchange the debt for securities. |
| 5. | Description of securities to be issued: |
| | (a) Class |
| | (b) Number |
| | (c) Price per security |
| | (d) Voting rights |
| 6. | Provide the following information if Warrants, (options) or other convertible securities are to be issued: |
| | (a) Number |
| | (b) Number of securities eligible to be purchased on exercise of Warrants (or options) |
| | (c) Exercise price |
| | (d) Expiry date |
| | |
| | |

(1) Indicate date each placee advanced or is expected to advance payment for securities. Provide

| 7. | Provid | e the following information if debt securities are to be issued: |
|-----|----------|--|
| | (a) | Aggregate principal amount |
| | (b) | Maturity date |
| | (c) | Interest rate |
| | (d) | Conversion terms |
| | (e) | Default provisions |
| 8. | finder's | e the following information for any agent's fee, commission, bonus of s fee, or other compensation paid or to be paid in connection with the nent (including warrants, options, etc.): |
| | (a) | Details of any dealer, agent, broker or other person receiving compensation in connection with the placement (name, address. It a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): |
| | (b) | Cash |
| | (c) | Securities |
| | (d) | Other |
| | (e) | Expiry date of any options, warrants etc |
| | (f) | Exercise price of any options, warrants etc |
| 9. | compe | whether the sales agent, broker, dealer or other person receiving ensation in connection with the placement is Related Person or has any relationship with the Issuer and provide details of the relationship |
| 10. | | be any unusual particulars of the transaction (i.e. tax "flow through" s, etc.). |
| 11. | State v | whether the private placement will result in a change of control. |

| 12. | issuar | e there is a change in the control of the Issuer resulting from the nce of the private placement shares, indicate the names of the new Iling shareholders. |
|-----|------------------------------|--|
| | | |
| 13. | restric subjec | purchaser has been advised of the applicable securities legislation ted or seasoning period. All certificates for securities issued which are at to a hold period bear the appropriate legend restricting their transferne expiry of the applicable hold period required by National Instrument 2. |
| 2. | Acqui | sition |
| 1. | location compl withou | le details of the assets to be acquired by the Issuer (including the on of the assets, if applicable). The disclosure should be sufficiently ete to enable a reader to appreciate the significance of the transaction at reference to any other material: See press release attached as adix "A" |
| | | |
| 2. | agreei disclos the sig | le details of the acquisition including the date, parties to and type of ment (eg: sale, option, license etc.) and relationship to the Issuer. The sure should be sufficiently complete to enable a reader to appreciate gnificance of the acquisition without reference to any other material: <a "b"."="" a"="" and="" appendix="" href="See releases attached as Appendix ">See releases attached as Appendix "A" and Appendix "B". |
| 3. | acquis | le the following information in relation to the total consideration for the sition (including details of all cash, securities or other consideration) and quired work commitments: |
| | (a) | Total aggregate consideration in Canadian dollars: <u>US\$7,146,582</u> . |
| | (b) | Cash: <u>US\$1,250,000</u> . |
| | (c) | Securities (including options, warrants etc.) and dollar value: <u>US\$500,000 of common shares, based on the 30-day VWAP as of the closing.</u> |
| | (d) | Other: Cash earnout of US\$5,396,582 to be paid over time based upon the net wholesale and net retail revenues generated from the San Jose facility. |
| | (e) | Expiry date of options, warrants, etc. if any: |
| | (f) | Exercise price of options, warrants, etc. if any: |

FORM 9 – NOTICE OF PROPOSED ISSUANCE OF LISTED SECURITIES January 2015 Page 4

| | (g) Work commitments: |
|----|---|
| 4. | State how the purchase or sale price was determined (e.g. arm's-length negotiation, independent committee of the Board, third party valuation etc). The purchase price and consideration were determined by arm's-length negotiation, guided by advice from the Issuer's financial adviser. |
| 5. | Provide details of any appraisal or valuation of the subject of the acquisition known to management of the Issuer: None |
| 6. | The names of parties receiving securities of the Issuer pursuant to the |

6. The names of parties receiving securities of the Issuer pursuant to the acquisition and the number of securities to be issued are described as follows:

| Name of Party (If not an individual, name all insiders of the Party) | Number and Type of Securities to be Issued | Dollar value per Security (CDN\$) | Conversion price (if applicable) | Prospectus Exemption | No. of Securities, directly or indirectly, Owned, Controlled or Directed by Party | Describe relationship to Issuer (1) |
|---|--|--|----------------------------------|-------------------------|---|---|
| DMMM & T, Inc. | To be determined. US\$500,000 in common shares | determined at the 30- day VWAP as of the closing date | N/A | N/A | nil | Arm's Length |

(1) Indicate if Related Person

- 7. Details of the steps taken by the Issuer to ensure that the vendor has good title to the assets being acquired: <u>Standard due diligence</u>.
- 8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the acquisition (including warrants, options, etc.): None
 - (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the acquisition (name, address. If a corporation, identify persons owning or exercising voting control

| | over 20% or more of the voting shares if known to the Issuer): |
|------------|--|
| (b) | Cash |
| (c) | Securities |
| (d) | Other |
| (e) | Expiry date of any options, warrants etc |
| (f) | Exercise price of any options, warrants etc |
| in conne | nether the sales agent, broker or other person receiving compensation oction with the acquisition is a Related Person or has any other this with the Issuer and provide details of the relationship. |
| If applied | able, indicate whether the acquisition is the acquisition of an interest |

Certificate Of Compliance

The undersigned hereby certifies that:

- 1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.
- 2. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
- 3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CSE Policy 1).
- 4. All of the information in this Form 9 Notice of Issuance of Securities is true.

| Dated September 4, 2018 . | |
|---------------------------|---------------------------------------|
| | Craig Eastwood |
| | Name of Director or Senior Officer |
| | "Craig Eastwood" |
| | Signature |
| | Chief Financial Officer |
| | Official Capacity |

Appendix "A"



Golden Leaf Holdings Announces Acquisition of Combined Cultivation, Production and Retail License in California

PORTLAND, Ore., Aug. 17, 2018 -- Golden Leaf Holdings Ltd. ("GLH" or the "Company") (CSE:GLH) (OTCQB:GLDFF), a cannabis company with cultivation, production and retail operations built around recognized brands, announced that on August 16, 2018, it signed a definitive agreement (the "Agreement") to acquire a combined cultivation, production and retail license in Northern California, dubbed a "Sweet 16" license. It is one of only 16 licenses of its kind issued by the City of San Jose that allows the holder to operate in a vertically integrated fashion.

"We are excited to introduce our brands and competencies to the 5th largest economy in the world. This is a natural progression given that we operate in the neighboring states of Oregon and Nevada. As part of an announcement we made August 13, 2018, we launched into the California market with our signing of the definitive agreement to purchase the assets of Tahoe Hydroponics Company, LLC and 11T Corp., which involves the acquisition of a ~28,800 ft² facility under development in Sacramento, California. Adding production and retail licenses complements our entry into California in a meaningful way. The approval of this single, multi-faceted license is expected to swiftly position us for this market. In anticipation of this development, my team has been working diligently on a wholesale and retail deployment plan, supported by investments in production and supply chain that we expect will generate revenues in a relatively short period of time from the date of closing," said William Simpson, CEO of Golden Leaf.

Following closing, Golden Leaf will lease the seller's facility to produce and distribute its branded products to 3rd party dispensaries and other wholesale sales channels in the State of California, as well as retrofit the section of the facility that currently operates as a retail outlet, into another branded, Chalice Farms store. The production facility will support additional Chalice Farms retail locations that may be opened in California in the future, aligning with the Company's go-to-market strategy.

Mr. Simpson added, "California's 'seed-to-sale' tracking requirements impact the supply chain of every licensed cannabis operation in the state. The tracking system "Metrc" being mandated by California is one that Golden Leaf already uses in Oregon and is fully conversant with. While other licensees come up to speed with how to implement this system, we will leverage our existing tried-and-tested standard operating procedures seamlessly."

Transaction Summary

Under the terms of the Contingent Asset Purchase Agreement, upon closing Golden Leaf will acquire the multi-use "Sweet 16" license, as well as certain assets of the seller including cash, inventory, equipment and contractual rights for US\$7,146,582, consisting of US\$1.25M in cash at closing and US\$500,000 of GLH stock based on the VWAP for the 30-days immediately preceding the closing date. The balance of the purchase price of US\$5,396,582 is cash earn-out consideration to be paid over time based upon the net wholesale and net retail revenues generated from the Company's San Jose facility. The lease is at market rates and the initial term of the lease agreement is for a period of five years. Closing of the transaction is subject to customary contingencies, including licensing approvals.

To be added to the email distribution list please email <u>GLH@kcsa.com</u> with 'GLH' in the subject line.

About Golden Leaf Holdings

Golden Leaf Holdings Ltd. is a Canadian company operating in multiple jurisdictions, including Canada, Oregon, Nevada, and California, with cultivation, production and retail operations built around recognized brands. Golden Leaf distributes its products through its branded Chalice Farms retail dispensaries, as well as through third party dispensaries. Golden Leaf's cannabis retail operations and products are designed with the customer in mind, focused on superlative in-store experience and quality products. Visit http://goldenleafholdings.com/ to learn more.

Investor Relations:

Phil Carlson KCSA Strategic Communications pcarlson@kcsa.com 212-896-1233

Media Contacts:

Anne Donohoe / Nick Opich KCSA Strategic Communications adonohoe@kcsa.com / nopich@kcsa.com 212-896-1265 / 212-896-1206

Company:

William Simpson Chief Executive Officer Golden Leaf Holdings Ltd.

William@chalicefarms.com

Disclaimer: This press release contains "forward-looking information" within the meaning of applicable securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the Company's future business operation, expectations of gross sales, expectation of revenues within a short time of closing, the opinions or beliefs of management and future business goals. Generally, forward looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including but not limited to general business, economic and competitive uncertainties, regulatory risks including risks related to the expected timing of the Company's participation in the Adult Use market, market risks, risks inherent in manufacturing operations and other risks of the cannabis industry. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward looking information. Forward-looking information is provided herein for the purpose of presenting information about management's current expectations relating to the future and readers are cautioned that such information may not be appropriate for other purpose. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws. This Release does not constitute an offer of securities for sale in the United States, and such securities may not be offered or sold in the United States absent registration or an exemption from registration or an exemption from registration.

THIS PRESS RELEASE, PROVIDED PURSUANT TO APPLICABLE CANADIAN REQUIREMENTS, IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN. THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION OR APPLICABLE EXEMPTION FROM REGISTRATION REQUIREMENTS.

Appendix "B"



Golden Leaf Reports Fiscal Second Quarter 2018 Results

Reported Record Quarterly Revenue of US\$3.7 million

TORONTO, Aug. 29, 2018 -- Golden Leaf Holdings Ltd. ("Golden Leaf" or the "Company") (CSE:GLH) (OTCQB:GLDFF), a cannabis company with cultivation, production and retail operations built around recognized brands, today announced financial results for the fiscal second quarter ended June 30, 2018, and a general business update.

Recent Business and Financial Highlights

- Record quarterly revenues of US\$3.7 million for Q2 2018, compared to US\$2.1 million for Q2 2017
- · Opened Chalice Farms dispensary, located in Happy Valley, Oregon
- · Signed letter of intent to acquire cannabis dispensary operation in Northern California
- Signed letter of intent to acquire two large cannabis cultivation facilities, one in Northern Nevada and another in Northern California
- · Hired Ryan Purdy as Vice President of Operations
- · Appointed Rick Miller to Board of Directors and to serve as its Chair
- · Announced election of John Varghese and Michael Crooke to the Board of Directors

Subsequent Events:

- · Announced definitive agreement to acquire "Sweet 16" license in Northern California
- · Announced definitive agreement to acquire Tahoe Hydroponics Company and 11T Corp
- · Introduced several cannabis concentrate product lines available in Nevada
- · Received license approval from City of Portland and State of Oregon for extraction facility
- Harvested its first crops from Medical Marijuana Group ("MMG"), its Canadian subsidiary, with yields that were 30% greater than originally forecasted

Mr. William Simpson, Chief Executive Officer of Golden Leaf Holdings, commented, "We posted strong year-over-year revenue growth of 76% for the second quarter of 2018 to reach record revenues of US\$3.7 million, primarily driven by the acquisition of our Chalice Farms retail operations, when compared to the second quarter of 2017. Adjusted EBITDA for the second quarter of 2018 was a loss of US\$3.2M, primarily driven by transaction costs and corporate expenses. During the quarter, we opened our sixth Chalice Farms location in Happy Valley, Oregon, which is now our second highest-grossing Chalice Farms location. In addition to retail operations, revenues from the Company's medical consulting division, as well as its Nevada wholesale operations and sales of our new Fruit Chews line in Oregon, continued to support our top line growth.

"We are strategically increasing our cultivation, wholesale and retail capabilities within our current and target markets to support the growing demand of the industry. With the impending legalization in Canada and the recent announcements to expand our presence in Nevada and enter the California market, we are focused on revenue growth and the responsible management of operating expenses on a per-share basis. Combining these efforts, our goal is to be cash-flow positive by the second half of 2019. Our work to build strong brands in key markets is central to the expansion of Golden Leaf, built on vertical integration where it is economically and operationally rational," concluded Mr. Simpson.

Q2 2018 Business Overview

• Oregon: Golden Leaf has state extraction and post-processing facilities and licenses to support its production of edibles and extracts products. In addition, it operates 7 licensed retail stores, 6 of which operate under the Chalice Farms brand. Its branded products are sold to both 3rd party retail stores on a wholesale basis, as well as directly through its 7 licensed retail stores. Currently, popular brands and products from other manufacturers are also procured and sold through the Company's 7 licensed retail stores.

In the second quarter, the Company officially opened its new Chalice Farms dispensary in Happy Valley, its 7th store in Oregon.

Subsequent to the quarter, the Company's Portland production facility received licensing approval from the Oregon Liquor Control Commission. Immediately after receiving the license, the Company initiated operation of the extraction equipment. Additionally, the commissioning of the Company's cultivation facility in Bald Peak is expected before the end of calendar year 2018.

During the second quarter of 2018, the Company continued to ramp production of its new Fruit Chews edible line in Oregon, which launched in the first quarter.

Nevada: Golden Leaf has state cultivation and production/extraction licenses to support its production of edibles and
extracts products. It sells its branded products through 3rd party retail stores on a wholesale basis, which are
currently available in 30-40 retail stores across Nevada. The delivery of those products is facilitated by a distributor in
Reno, Nevada.

Through its wholly-owned subsidiary, Greenpoint Nevada, the Company introduced several cannabis concentrate product lines in the Nevada market throughout the second quarter, including Golden Tinctures offered in Orange, Cherry, Mint and Strawberry flavors, Golden Private Stash distillate vape cartridges, and its Golden CBD product lines.

On August 10, 2018, the Company signed a definitive agreement to acquire the assets of Tahoe Hydroponics Company and 11T Corp. (collectively "Tahoe"), following the signing of an LOI in May. With a fully-built ~21,600 ft² facility in Carson City already producing ~4,000 pounds per annum, Tahoe brings material cultivation capacity to Golden Leaf's Nevada operations.

The Company also plans to open retail dispensaries in Nevada and is in negotiations on several opportunities, all contingent on it receiving retail licenses.

The consideration for the acquisition of the assets of Tahoe consists of:

- In respect of the assets of Tahoe Hydroponics, a cash payment of US\$8.5 million plus that number of common shares of the Company such that on closing, the vendors of the assets of Tahoe Hydroponics will hold 25% of the outstanding common shares of the Company (less the shares to be issued to the vendors of the 11T assets as described below) plus a number of common shares of the Company equal to US\$1.35 million, using the 20-day volume weighted average price of the common shares determined for the 20 days immediately prior to the closing.
- In respect of the assets of 11T, a number of common shares of the Company equal to US\$5 million using the 20day volume weighted average price of the common shares determined for the 20 days immediately prior to the closing.
- California: Upon closing of the definitive agreements signed on August 13th, 2018 and August 17th, 2018, the Company will have a ~28,800 ft² cultivation facility in Sacramento, which is currently under development; and a combined cultivation, production and retail facility in San Jose. The aforementioned definitive agreements are expected to provide an immediate foothold in the state of California. The Sacramento cultivation facility is anticipated to be operational in Q1 2019.
 - The consideration for the San Jose license and certain associated assets of the seller, including cash, inventory, equipment and contractual rights, is US\$7,146,582, consisting of US\$1,250,000 in cash at closing plus a number of common shares of the Company equal to US\$500,000, using the 30-day volume weighted average price of the common shares determined for the 30 days immediately prior to the closing, plus US\$5,396,582 in cash earn-out consideration to be paid over time based upon the net wholesale and net retail revenues generated.
- Canada: The Company's subsidiary, Medical Marijuana Group (MMG), has a cultivation license from Health Canada.
 The Company's subsidiary Medical Marijuana Group Consulting (MMGC), is a medical marijuana consulting company
 that secures high-value medical marijuana patients and educates and refers them to Licensed Producers for their
 product.

In early July, MMG harvested its first crops at its state-of-the-art grow facility in Ontario. The harvested crops, which had yields that were 30% greater than originally forecasted, mirrored yields from Canada's premier cannabis companies. MMG has secured buyers to take delivery of the finished product once the Company receives its final sales license.

As of the end of the second quarter, MMGC had approximately 4,600 medical patients.

• **New management:** In May, Ryan Purdy joined the team as Vice President of Operations to lead overall supply chain strategy and execution, including vendor selection, production planning, procurement and logistics.

In July, the Company announced the election of John Varghese and Michael Crooke to the Board of Directors, effective June 29, 2018. John Varghese is now the chair of the Compensation Committee and also joined the Audit and Disclosure Committees. Michael Crooke joined the Nominating and Corporate Governance Committees.

Fiscal Second Quarter Ended June 30, 2018 Financial Results

For the quarter ended June 30, 2018 ("Q2 2018"), net revenue was US\$3.7 million as compared to US\$2.1 million for the same three-month period in 2017 ("Q2 2017"). The 76% year-over-year increase largely reflects the addition of the Chalice Farms retail revenue stream, the addition of the Company's medical consulting revenues and the Company's Nevada wholesale operations, offset slightly by declines in wholesale revenues in Oregon.

Gross profit was US\$940,000 or 26% of net revenue, for Q2 2018, compared with US\$402,000 or 19% of net revenue in Q2 2017. Q2 2018 gross margins increased primarily due to the addition of gains on fair market value of biological assets from the Company's cultivation subsidiary.

Operating expenses were US\$4.6 million USD for Q2 2018, compared with US\$2.7 million in Q2 2017, which is largely attributable to the addition of the Chalice Farms retail business which was acquired in July 2017, and higher corporate costs.

Adjusted EBITDA loss was US\$3.2 million for Q2 2018, compared with a loss of US\$1.9 million for Q2 2017, primarily as a result of increased transaction costs and corporate expenses within G&A. Adjusted EBITDA is defined by the Company as earnings before taxes, depreciation and amortization, less certain non-cash equity compensation expenses, including impairments, one-time transaction fees and all other non-cash items. The Company considers Adjusted EBITDA an important operational measure for the business.

Net income for Q2 2018 was US\$3.2 million or US\$0.01 per share, compared with a net loss of US\$1.7 million or \$0.01 per share loss, for Q2 2017. Net income for Q2 2018 benefited from non-operating income of US\$7.3 million related to favorable changes in the fair value of warrant and debt liabilities.

As of June 30, 2018, the Company had approximately US\$22.6 million in current assets, compared with US\$11.6 million in current assets at December 31, 2017. The increase is largely because of the bought deal financing which was completed on January 31, 2018, in addition to proceeds from warrant exercises. Total assets increased to US\$86.7 million at June 30, 2018, compared to US\$75.8 million at December 31, 2017, also due primarily to the bought deal financing completed in January.

Investor Conference Call

GLH's management, led by William Simpson, Chief Executive Officer, will hold a conference call at 4:30 PM ET today, Wednesday, August 29, 2018, to report its financial results for the second quarter ended June 30, 2018.

The dial-in information for the conference call is as follows:

Program Title: Golden Leaf Holdings Second Quarter 2018 Financial Results Call

Canada & U.S.: (877) 423-9813 International: (201) 689-8573

Participants must request the Golden Leaf Holdings Call.

A live audio webcast will be available online on Golden Leaf's website at goldenleafholdings.com, where it will be archived for one year.

An audio replay of the conference call will be available through midnight September 12, 2018 by dialing +1 (844) 512-2921 from the U.S. or Canada, or +1 (412) 317-6671 from international locations, Conference ID: 13682739.

To be added to the Golden Leaf email distribution list, please email GLH@kcsa.com with 'GLH' in the subject line.

About Golden Leaf Holdings

Golden Leaf Holdings Ltd. is a Canadian company operating in multiple jurisdictions, including Oregon, Nevada and Canada, with cultivation, production and retail operations built around recognized brands. Golden Leaf distributes its products through its branded Chalice Farms retail dispensaries, as well as through third party dispensaries. Golden Leaf's cannabis retail operations and products are designed with the customer in mind, focused on superlative in-store experience and quality products. Visit http://goldenleafholdings.com/ to learn more.

Investor Relations:

Phil Carlson KCSA Strategic Communications GLH@kcsa.com 212-896-1220 / 212-896-1233

Media Relations:

Anne Donohoe / Nick Opich KCSA Strategic Communications adonohoe@kcsa.com/nopich@kcsa.com 212-896-1265 / 212-896-1206

Company:

William Simpson
Chief Executive Officer
Golden Leaf Holdings Ltd.
503-201-0659
William@chalicefarms.com

Disclaimer: This press release contains "forward-looking information" within the meaning of applicable securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the Company's future business operation, expectations of gross sales, the opinions or beliefs of management and future business goals, statements regarding the timing for opening of the Company's sixth Chalice Farms dispensary. Generally, forward looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors

that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including but not limited to general business, economic and competitive uncertainties, regulatory risks including risks related to the expected timing of the Company's participation in the Adult Use market, market risks, risks inherent in manufacturing operations and other risks of the cannabis industry. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward looking information. Forward-looking information is provided herein for the purpose of presenting information about management's current expectations relating to the future and readers are cautioned that such information may not be appropriate for other purpose. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws. This Release does not constitute an offer of securities for sale in the United States, and such securities may not be offered or sold in the United States absent registration or an exemption from registration.

GOLDEN LEAF HOLDINGS LTD.

Interim Condensed Consolidated Statement of Operations and Comprehensive Gain (Loss) (Unaudited) For the three and six months ended June 30, 2018 and 2017 (Expressed in U.S. dollars)

| | | For the three months ended June 30, | | ths ended June), |
|--|----------------------|-------------------------------------|----------------|----------------------|
| | 2018 | 2017 | 2018 | 2017 |
| Revenues | | | | |
| Product sales | \$ 3,671,738 | \$ 2,089,393 | \$ 6,854,727 | \$ 4,348,487 |
| Consulting revenue | 9,898 | - | 27,176 | - |
| Total Revenue | \$ 3,681,636 | \$ 2,089,393 | \$ 6,881,903 | \$ 4,348,487 |
| Inventory expensed to cost of sales | 3,029,795 | 1,530,212 | 5,754,508 | 3,368,899 |
| Production costs | 113,753 | 157,057 | 411,227 | 339,065 |
| Gross margin before the undernoted | 538,088 | 402,124 | 716,168 | 640,523 |
| Fair value changes in biological assets included | | | | |
| in inventory sold and other inventory charges | 10,518 | - | 129,648 | - |
| Gain on changes in fair value of biological assets Note 7 | (412,360) | _ | (706,257) | _ |
| Gross profit | \$ 939,930 | \$ 402,124 | \$ 1,292,777 | \$ 640,523 |
| Closs profit | ψ 939,930 | ψ 402,124 | Ψ 1,292,777 | Ψ 040,323 |
| Expenses | | | | |
| General and administration | 3,270,258 | 2,058,257 | 6,066,052 | 3,656,530 |
| Share based compensation Note 15 | 567,969 | 215,221 | 1,643,421 | 376,569 |
| Professional fees paid with equity | | | | |
| instruments | - | 113,071 | - | 167,491 |
| Sales and marketing | 440,751 | 287,289 | 824,052 | 566,212 |
| Note 8, Depreciation and amortization 9 | 358,516 | 71,128 | 703,795 | 133,303 |
| · | \$ 4,637,494 | \$ 2,744,966 | \$ 9,237,320 | \$ 4,900,105 |
| Total expenses | φ 4,03 <i>1</i> ,494 | \$ 2,744,900 | φ 9,237,320 | \$ 4,900,103 |
| Loss before undernoted items | \$ (3,697,564) | \$ (2,342,842) | \$ (7,944,543) | \$ (4,259,582) |
| Interest expense | 266,317 | 312,411 | 915,575 | 857,432 |
| Transaction costs | - | - | 471,900 | - |
| Loss on disposal of assets | 5,000 | 294,200 | 5,000 | 294,200 |
| Impairment of financing lease receivable | - | 27,422 | - | 54,844 |
| Other loss | 36,723 | 161,903 | (122,403) | 162,828 |
| Gain on change in fair value of warrant liability Note 12 | (4,415,480) | (82,694) | (10,627,702) | (238,379) |
| Gain on change in fair value of liabilities Note 10 | (2,841,987) | (1,541,097) | (9,970,603) | (1,585,790) |
| Gain (loss) before income taxes | \$ 3,251,863 | \$ (1,514,987) | \$ 11,383,690 | \$ (3,804,717) |
| Current income tax expense | 8,434 | 200,000 | 8,434 | 200,000 |
| Net Gain (Loss) | \$ 3,243,429 | \$ (1,714,987) | \$ 11,375,256 | \$ (4,004,717) |
| Other comprehensive loss | | | | |
| Cumulative translation adjustment | \$ 34,146 | | \$ 53,263 | |

| Comprehensive Gain (Loss) | \$ 3,209,283 | \$ (1,714,987) | \$ 11,321,993 | \$ (4,004,717) |
|--|--------------|----------------|---------------|----------------|
| Basic and diluted gain (loss) per share | \$ 0.01 | \$ (0.01) | \$ 0.02 | -0.03 |
| Weighted average number of common shares | | | | |
| outstanding | 575,776,971 | 143,604,908 | 555,451,438 | 131,045,274 |

GOLDEN LEAF HOLDINGS LTD.

Interim Condensed Consolidated Statement of Financial Position (Unaudited) As at June 30, 2018 and December 31, 2017 (Expressed in U.S. dollars)

| | | June 30, 2018 | December 31, 2017 |
|--|---------|----------------------|-------------------|
| ASSETS | | | |
| CURRENT | | | |
| Cash | | \$ 15,702,963 | \$ 6,009,447 |
| Accounts receivable | Note 6 | 270,919 | 377,746 |
| Other receivables | | 136,234 | - |
| Income tax recoverable | | 748,200 | 432,000 |
| Sales tax recoverable | | 549,449 | 442,832 |
| Biological assets | Note 7 | 402,675 | 90,627 |
| Inventory | Note 7 | 4,059,927 | 3,623,255 |
| Prepaid expenses and deposits | | 720,415 | 348,176 |
| Assets held for sale | | 35,274 | 305,274 |
| Total current assets | | \$ 22,626,056 | \$ 11,629,357 |
| Property, plant and equipment | Note 8 | 6,071,676 | 5,956,910 |
| Intangible assets | Note 9 | 26,075,826 | 26,227,116 |
| Goodwill | 11010 0 | 31,971,398 | 31,971,398 |
| Total assets | | \$ 86,744,956 | \$ 75,784,781 |
| LIABILITIES | | | |
| CURRENT | | | |
| Accounts payable and accrued liabilities | | \$ 1,127,110 | \$ 2,867,735 |
| Interest payable | | ψ 1,127,110 1,594 | 48,524 |
| Current portion of long-term debt | Note 11 | 40,371 | 131,610 |
| Current portion of convertible debentures | Note 11 | 40,071 | 131,010 |
| carried at fair value | Note 10 | _ | 271,245 |
| Derivative liability | Note 10 | 92,178 | 61,044 |
| Total current liabilities | | \$ 1,261,253 | \$ 3,380,158 |
| | | | |
| Long term debt | Note 11 | 64,455 | 80,381 |
| Note payable | Note 10 | 313,816 | 389,916 |
| Convertible debentures carried at fair value | Note 10 | 12,016,126 | 30,360,225 |
| Consideration payable | | 9,527,350 | 9,527,350 |
| Warrant liability | Note 12 | 4,406,297 | 14,300,616 |
| Total liabilities | | \$ 27,589,297 | \$ 58,038,646 |
| SHAREHOLDERS' EQUITY | | | |
| Share capital | Note 13 | \$ 138,002,232 | \$ 108,552,681 |
| Warrant reserve | Note 14 | 4,078,120 | 5,083,561 |
| Share option reserve | Note 15 | 2,100,540 | 1,087,640 |
| Contributed surplus | | 59,940 | 59,940 |
| Accumulated other comprehensive loss | | -43,435 | 9,828 |
| Deficit | | -85,041,738 | -97,047,515 |
| | | | 2.,2,0.0 |

| Total shareholders' equity | \$ 59,155,659 | \$ 17,746,135 |
|--|---------------|---------------|
| Total liabilities and shareholders' equity | \$ 86,744,956 | \$ 75,784,781 |

| Adjusted EBITDA | | | | |
|---|---|----------------|----------------|----------------|
| | For the three months ended June 30, For the six months ended June 30, | | | |
| | 2018 | 2017 | 2018 | 2017 |
| Income (loss) before income taxes Adjustments: | 3,251,863 | (1,514,987) | 11,383,690 | (3,804,717) |
| Net impact, fair value of biological assets | (401,842) | - | (576,609) | - |
| Depreciation and amortization | 358,516 | 71,128 | 703,795 | 133,303 |
| Fair value changes on debt and equity instruments | (7,257,467) | (1,623,791) | (20,598,305) | (1,824,169) |
| Share based compensation | 567,969 | 328,292 | 1,643,421 | 544,060 |
| Interest expense, net | 266,317 | 312,411 | 915,575 | 857,432 |
| Transaction costs | - | - | 471,900 | - |
| Impairments and other | 36,723 | 189,325 | (122,403) | 217,672 |
| Loss on disposal | 5,000 | 294,200 | 5,000 | 294,200 |
| Adjusted EBITDA operational Gain (Loss) | \$ (3,172,921) | \$ (1,943,422) | \$ (6,173,936) | \$ (3,582,219) |

Adjusted EBITDA Disclaimer: Adjusted EBITDA is defined by the Company as earnings before interest, taxes, depreciation, amortization, less certain non-cash compensation expenses, including impairments, one-time transaction fees and all other noncash items. Adjusted EBITDA is a non-GAAP financial measure which does not have any standardized meaning prescribed by IFRS and is therefore unlikely to be comparable to similar measures presented by other issuers. The Company considers this Adjusted EBITDA an important figure to show the true day to day operational picture of the business. It should not be considered in isolation as a substitute for measures of performance prepared in accordance with the IFRS.